Stockreport

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility [Yahoo! Finance]

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF XOLREMDI, the first drug indicated in patients with WHIM syndrome, received U.S. FDA approval in April 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceutical [Read more]